Summary of Significant Accounting Policies - Schedule of Concentration (Details)
|
12 Months Ended |
Dec. 31, 2019 |
Dec. 31, 2018 |
Dec. 31, 2017 |
| Janssen | Accounts Receivable | Credit Concentration Risk |
|
|
|
| Revenue Initial Application Period Cumulative Effect Transition [Line Items] |
|
|
|
| Concentration risk percentage |
29.00%
|
27.00%
|
31.00%
|
| Janssen | Revenues Net | Customer Concentration Risk |
|
|
|
| Revenue Initial Application Period Cumulative Effect Transition [Line Items] |
|
|
|
| Concentration risk percentage |
28.00%
|
29.00%
|
33.00%
|
| Biogen | Revenues Net | Customer Concentration Risk |
|
|
|
| Revenue Initial Application Period Cumulative Effect Transition [Line Items] |
|
|
|
| Concentration risk percentage |
17.00%
|
10.00%
|
|
| Cardinal Health | Accounts Receivable | Credit Concentration Risk |
|
|
|
| Revenue Initial Application Period Cumulative Effect Transition [Line Items] |
|
|
|
| Concentration risk percentage |
12.00%
|
|
|
| Cardinal Health | Revenues Net | Customer Concentration Risk |
|
|
|
| Revenue Initial Application Period Cumulative Effect Transition [Line Items] |
|
|
|
| Concentration risk percentage |
|
13.00%
|
|
| AmerisourceBergen | Accounts Receivable | Credit Concentration Risk |
|
|
|
| Revenue Initial Application Period Cumulative Effect Transition [Line Items] |
|
|
|
| Concentration risk percentage |
10.00%
|
|
|
| Acorda | Accounts Receivable | Credit Concentration Risk |
|
|
|
| Revenue Initial Application Period Cumulative Effect Transition [Line Items] |
|
|
|
| Concentration risk percentage |
|
15.00%
|
14.00%
|
| Acorda | Revenues Net | Customer Concentration Risk |
|
|
|
| Revenue Initial Application Period Cumulative Effect Transition [Line Items] |
|
|
|
| Concentration risk percentage |
|
10.00%
|
13.00%
|